Literature DB >> 21372171

Glycogen synthase kinase-3β is a functional modulator of serotonin-1B receptors.

L Chen1, W Zhou, P C Chen, I Gaisina, S Yang, X Li.   

Abstract

Glycogen synthase kinase-3 (GSK3) is a constitutively active protein kinase that is involved in neuronal regulation and is a potential pharmacological target of neurological disorders. We found previously that GSK3β selectively interacts with 5-hydroxytryptamine-1B receptors (5-HT1BR) that have important functions in serotonin neurotransmission and behavior. In this study, we provide new information supporting the importance of GSK3β in 5-HT1BR-regulated signaling, physiological function, and behaviors. Using molecular, biochemical, pharmacological, and behavioral approaches, we tested 5-HT1BR's interaction with G(i)α(2) and β-arrestin2 and 5-HT1BR-regulated signaling in cells, serotonin release in mouse cerebral cortical slices, and behaviors in wild-type and β-arrestin2 knockout mice. Molecular ablation of GSK3β and GSK3 inhibitors abolished serotonin-induced change of 5-HT1BR coupling to G(i)α(2) and associated signaling but had no effect on serotonin-induced recruitment of β-arrestin2 to 5-HT1BR. This effect is specific for 5-HT1BR because GSK3 inhibitors did not change the interaction between serotonin 1A receptors and G(i)α(2). Two GSK3 inhibitors, N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea (AR-A014418) and 3-(5-bromo-1-methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione (BIP-135), efficiently abolished the inhibitory effect of the 5-HT1BR agonist anpirtoline on serotonin release in mouse cerebral cortical slices. GSK3 inhibitors also facilitated the 5-HT1BR agonist anpirtoline-induced behavioral effect in the tail suspension test but spared anpirtoline-induced locomotor activity. These results suggest that GSK3β is a functional selective modulator of 5-HT1BR-regulated signaling, and GSK3 inhibitors fine-tune the physiological and behavioral actions of 5-HT1BR. Future studies may elucidate the significant roles of GSK3 in serotonin neurotransmission and implications of GSK3 inhibitors as functional selective modulators of 5-HT1BR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372171      PMCID: PMC3102555          DOI: 10.1124/mol.111.071092

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).

Authors:  D G Smith; M Buffet; A E Fenwick; D Haigh; R J Ife; M Saunders; B P Slingsby; R Stacey; R W Ward
Journal:  Bioorg Med Chem Lett       Date:  2001-03-12       Impact factor: 2.823

Review 2.  Multiplicity of mechanisms of serotonin receptor signal transduction.

Authors:  J R Raymond; Y V Mukhin; A Gelasco; J Turner; G Collinsworth; T W Gettys; J S Grewal; M N Garnovskaya
Journal:  Pharmacol Ther       Date:  2001 Nov-Dec       Impact factor: 12.310

Review 3.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

4.  Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT(1B) receptors in transfected BE(2)-C neuroblastoma cells is inhibited by RGS4.

Authors:  A M Leone; M Errico; S L Lin; D S Cowen; A M Lione
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

5.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

6.  Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances.

Authors:  Abigail Polter; Eléonore Beurel; Sufen Yang; Rakesha Garner; Ling Song; Courtney A Miller; J David Sweatt; Lori McMahon; Alfred A Bartolucci; Xiaohua Li; Richard S Jope
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

7.  Activation of Akt1 by human 5-hydroxytryptamine (serotonin)1B receptors is sensitive to inhibitors of MEK.

Authors:  E H Hsu; A C Lochan; D S Cowen
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

Review 8.  GSK3 takes centre stage more than 20 years after its discovery.

Authors:  S Frame; P Cohen
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

Review 9.  The 5-HT1B receptor: behavioral implications.

Authors:  M S Clark; J F Neumaier
Journal:  Psychopharmacol Bull       Date:  2001

10.  Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET).

Authors:  S Angers; A Salahpour; E Joly; S Hilairet; D Chelsky; M Dennis; M Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  14 in total

Review 1.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 2.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

3.  PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Wei-Chun J Hsu; Norelle C Wildburger; Sigmund J Haidacher; Miroslav N Nenov; Oluwarotimi Folorunso; Aditya K Singh; Brent C Chesson; Whitney F Franklin; Ibdanelo Cortez; Rovshan G Sadygov; Kelly T Dineley; Jay S Rudra; Giulio Taglialatela; Cheryl F Lichti; Larry Denner; Fernanda Laezza
Journal:  Exp Neurol       Date:  2017-05-15       Impact factor: 5.330

4.  Noradrenergic antidepressant responses to desipramine in vivo are reciprocally regulated by arrestin3 and spinophilin.

Authors:  Christopher Cottingham; Xiaohua Li; Qin Wang
Journal:  Neuropharmacology       Date:  2012-02-19       Impact factor: 5.250

Review 5.  A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health.

Authors:  Jean-Martin Beaulieu
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

Review 6.  Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.

Authors:  Olivia O'Leary; Yvonne Nolan
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

7.  Behavioral stress-induced activation of FoxO3a in the cerebral cortex of mice.

Authors:  Wenjun Zhou; Ligong Chen; Sufen Yang; Fuzeng Li; Xiaohua Li
Journal:  Biol Psychiatry       Date:  2011-10-05       Impact factor: 13.382

8.  Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission.

Authors:  Abigail M Polter; Xiaohua Li
Journal:  Front Mol Neurosci       Date:  2011-10-24       Impact factor: 5.639

9.  The effects of glycogen synthase kinase-3beta in serotonin neurons.

Authors:  Wenjun Zhou; Ligong Chen; Jodi Paul; Sufen Yang; Fuzeng Li; Karen Sampson; Jim R Woodgett; Jean Martin Beaulieu; Karen L Gamble; Xiaohua Li
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  Glycogen synthase kinase-3ß supports serotonin transporter function and trafficking in a phosphorylation-dependent manner.

Authors:  Durairaj Ragu Varman; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  J Neurochem       Date:  2020-09-07       Impact factor: 5.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.